In recent years, immunity activation therapies based on cytokine drugs are anticipated for promoting the body's immune system to treat diseases such as cancer, but there have been several problems: in some cases the activity of the cytokine drugs was too weak to achieve sufficient treatment results, in other cases serious side effects were caused by large doses, and in still others the cost burden on patients was too high. For that reason, enhancing therapeutic activity has become an important issue for immunity activation treatment using cytokine drugs, and there is a need for an immunity activation drug adjuvant capable of enhancing the effect of cytokine drugs and thereby suppressing the amount thereof used. The purpose of the present invention is to provide a safe and low-cost immunity activation treatment adjuvant therapy drug capable of enhancing the effect of cytokine drugs. The inventors discovered that the effect of immunity activation therapy based on cytokine drugs can be enhanced by utilizing implantation of ß-tricalcium phosphate (TCP) into the body, said implantation functioning to allow activity, migration and accumulation of immune cells； this discovery led to the perfection of the present invention.
